Heat Biologics, Inc. (HTBX) financial statements (2021 and earlier)

Company profile

Business Address 627 DAVIS DRIVE
MORRISVILLE, NC 27560
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:151520242821
Cash and cash equivalents9914182221
Short-term investments66666 
Other undisclosed cash, cash equivalents, and short-term investments  0 (0) 
Receivables000000
Prepaid expense000000
Other current assets0   00
Other undisclosed current assets001012
Total current assets:151620242924
Noncurrent Assets
Property, plant and equipment111111
Other noncurrent assets1089988
Total noncurrent assets:1199999
TOTAL ASSETS:262430343832
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities333333
Accounts payable222211
Accrued liabilities211122
Deferred revenue3  0
Debt0000  
Business combination, contingent consideration, liability211111
Other undisclosed current liabilities    13
Total current liabilities:854457
Noncurrent Liabilities
Long-term debt and lease obligation2000  
Finance lease, liability0   
Operating lease, liability2000
Liabilities, other than long-term debt333223
Deferred revenue0000
Deferred tax liabilities, net01
Deferred income tax liabilities0   
Other liabilities 00000
Business combination, contingent consideration, liability222222
Other undisclosed noncurrent liabilities 00000
Total noncurrent liabilities:433333
Total liabilities:13887810
Stockholders' equity
Stockholders' equity attributable to parent141722273025
Common stock000000
Additional paid in capital118118117117115104
Accumulated other comprehensive income (loss)(0)0(0)(0)(0)(0)
Accumulated deficit(105)(101)(95)(90)(85)(80)
Stockholders' equity attributable to noncontrolling interest(0)(0)(0)(0)(0)(2)
Total stockholders' equity:131622263022
TOTAL LIABILITIES AND EQUITY:262430343832

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Gross profit:200122
Operating expenses(5)(6)(5)(7)(8)(6)
Operating loss:(3)(6)(5)(6)(6)(4)
Nonoperating income000000
Investment income, nonoperating 000 0
Other nonoperating income (expense) (0)(0)0 0
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)     
Loss from continuing operations before equity method investments, income taxes:(3)(6)(5)(6)(5)(4)
Other undisclosed income from continuing operations before income taxes0     
Loss from continuing operations before income taxes:(3)(6)(5)(6)(5)(4)
Income tax expense (benefit)   (0)00
Net loss:(3)(6)(5)(6)(5)(4)
Net income (loss) attributable to noncontrolling interest(0)00000
Net loss available to common stockholders, diluted:(3)(6)(5)(6)(5)(4)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
Net loss:(3)(6)(5)(6)(5)(4)
Other comprehensive income (loss)(0)00(0)0 
Other undisclosed comprehensive income     0
Comprehensive loss:(3)(6)(5)(6)(5)(4)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(0)00000
Comprehensive loss, net of tax, attributable to parent:(3)(6)(5)(6)(5)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: